646jili com
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Symbotic Inc. (“Symbotic”) common stock (NASDAQ: SYM). SYM designs and develops an A.I.-powered robotic software platform for use in warehouses. After the market closed on November 18, 2024, SYM announced its fiscal fourth quarter and full year 2024 results. In addition, Symbotic disclosed it would need to restate its financial statements for the first three quarters of fiscal year 2024 with respect to its accounting of goods and services received. Before the market opened on November 27, 2024, Symbotic announced it wouldn’t be able to file its Annual Report on Form 10-K for the fiscal year ended September 28, 2024. Symbotic disclosed on November 25, 2024, it had identified errors in its revenue recognition related to cost overruns that are not billable on certain deployments, which additionally impacted system revenue recognized in the first three quarters of fiscal 2024. The total impact of the errors will lower system revenue, system gross profit, income (loss) before income tax, and adjusted EBITDA by $30 million to $40 million for fiscal 2024. Furthermore, Symbotic lowered its fiscal 2025 revenue and adjusted EBITDA guidance by 3.0% and 51.7%, respectively. Pre-market trading for Symbotic on November 27, 2024 indicates Symbotic’s stock price will open down over 31% to $25.34 per share. Investors who lost over $25,000 trading in Symbotic common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com . Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com . Attorney Advertising: Prior Results Do Not Guarantee a Similar Outcome. Wolf Popper LLP Adam Savett 845 Third Avenue New York, NY 10022 Tel.: (212) 451-9655 Email: asavett@wolfpopper.com
It’s not 2016 again. President-elect Donald Trump is off to a strong start with markedly fewer obstructions than the last time he won. In football terms, he has a lot of green space ahead of him. In nautical terms, it’s plain sailing. In political terms, it might not be a honeymoon, but no one is throwing any furniture, either. Naturally, there are all sorts of potential pitfalls. Some of Trump’s more controversial cabinet picks could, if confirmed, blow up once they are in place (does anyone believe that RFK, Jr.’s tenure at Health and Human Services will be smooth and uneventful?). Republicans only have two votes to spare in the House. Events will take a hand, and so will Trump’s mercurial nature. We are in a much different place than eight years ago, though. When Trump won in 2016, the shock to the system was so great that the body politic reacted strongly and reflexively. Trump was treated as a virus and every antibody attacked him, from activists in the street to the director of the FBI. This time, the reaction is much more muted. Despite all the fevered warnings of an existential threat to democracy, when former top Kamala Harris advisers did an election post-mortem on the podcast “Pod Save America,” they talked about how they could do better next time — in other words, there will be a next time. Despite the insistence of his enemies that Trump can’t be “normalized,” he’s been an inescapable fixture of American politics for about a decade now, with at least another four years ahead (he could well continue to dominate the Republican Party even after his second term ends). Like it or not, Trump is mainstream. He shows up at those most American events — football games and MMA fights — and gets applause. He eats McDonald’s. He himself is part of the pop culture. The time, unlike in 2016, there were no protests after he won the election, or any effort to get so-called faithless electors to keep him from assuming office. There is no cloud of illegitimacy over his victory. He won more convincingly than in 2016, carrying the popular vote and denying his opponents the opportunity to say he only won via the technicality and anachronism of the Electoral College. There has been no widely believed conspiracy theory — spun out of vaporous nonsense and hysteria — that his victory was the result of collusion with a hostile foreign power. Relatedly, this time Trump doesn’t have a bogus investigation hanging over his head. The Russiagate probe blighted the initial years of his first term. Now, the legal decks are clearing. Whereas Special Counsel Robert Mueller was about to enter the stage after Trump won in 2016, Special Counsel Jack Smith is exiting it. As Trump enters office a second time, he is going to be less legally encumbered than he’s been in years. In 2016, Trump got elected despite a catastrophic unfavorable rating in the polling. This time, he was closer to a break-even favorable/unfavorable rating in some pre-election surveys, and he’s ticked upward since. In a recent CBS poll, 59% of people said they approve of his transition. If in 2016 it felt like Trump faced a stiff head-wind at the outset, this time he has the wind — or at least a pleasant breeze — at his back. Trump is already looming much larger than the incumbent president who, with the exception of the pardon of his son, has nearly disappeared. When Biden shuffles off the stage he won’t, like Hillary Clinton , be complaining that Trump stole the election from him. If Biden is going to be bitter about anything, it will be about the machinations that denied him a Democratic nomination that he had already won. None of this means that Trump is guaranteed success in the crucial first two years of his presidency. But the conditions favor him in a way they decidedly didn’t eight years ago. Twitter: @RichLowryTrump’s promises to conservatives raise fears of more book bans in US
Is a liberal arts degree useless if you want to succeed in life? Not at all.Internal polling for Kamala Harris never showed her leading Donald Trump in the race for the presidency, her campaign team has revealed. Thrust into the race with just over three months until election day, Harris was behind from the start and could not get herself in front at any point, even as published polls suggested that she had overtaken the former president. Although it was widely acknowledged that the election results would be close, many pundits picked Harris, 60, as the likely winner. Instead Trump, 78, won all seven swing states and the popular vote, expanding his support from 2020 across nearly every voting bloc to crown an extraordinary political comeback . The Republicans also won both chambers of Congress , giving Trump sweeping power to enact his “America First” agenda.
Bengals optimistic heading into new month, meeting vs. SteelersIndia, Japan Hold First Round of Dialogue on Economic Security, Strategic Trade in Tokyo
DESPITE not going through on the first count in Limerick City, as many predicted, veteran TD Willie O’Dea is confident of his chances of retaining his seat and confident in his Fianna Fáil party to make a sweep of seats across today and tomorrow. Deputy O’Dea gleaned the highest number of first preference votes in the first count at Limerick Racecourse today, falling just short of the 8,435 quota with 8,214 first preference votes. He is followed closely by Kieran O’Donnell of Fine Gael on 6,133 and Sinn Féin’s Maurice Quinlivan on 5,936, which means the dogfight for the fourth city seat is now on. Dee Ryan (FF) got 2,831 votes on the first round, Maria Byrne (FG) took 2,813, Elisa O’Donovan got 2,808, and Labour’s Conor Sheehan had 2,733. Others tipped to take the seat, Independent Frankie Daly (2,034), Sarah Beasley of Aontú (1,977), and Green Party TD Brian Leddin (1,782), look to be falling short at this point as Dean Lillis (IND) and Michelle Hayes (IND) were eliminated. Confident out in front, Willie O’Dea said he feels “fantastic” in current position, however cast a foreboding shadow over one element of yesterday’s vote. “If I can strike one cautionary note on an otherwise joyous day, I’m unhappy with the turnout,” O’Dea said. “My understanding is that the turnout here is something in the order of about 55 per cent or thereabouts. That means that out of every 20 Limerick with the right to vote, nine didn’t exercise that right. “And what you see not just here in Limerick but nationally, is a gradual reduction in the turnout from election to election, and that does demonstrate a sort of erosion of confidence in democracy, which is very serious given the world.” And despite the “monumental cock-up” on yesterday’s ballot which saw some names put out of the legally mandated alphabetic order on the city ballot papers, O’Dea says he won’t be making any legal challenge on the validity of the vote. “It was an incredible cock-up, let’s call a spade a spade, how people didn’t seem to fully understand the alphabet, I can never get my head around. But the photographs were there and I don’t really think that where you appear in the ballot paper, if you’re not that far away from where you’d appear normally, would make any material difference anyway,” he said. Making an early call for a Fianna Fáil/Fine Gael coalition, O’Dea claimed that the Irish public yesterday voted for ‘stability’. “My understanding around the country is that Fianna Fáil would be the biggest party, but Fianna Fáil and Fine Gael between them will have almost enough, if not enough, to form a government on their own. So it shows you that the Irish people are conscious of the need for a stable government in these troubling times, and that’s the way they voted, and that’s the decision of the electorate,” he said. The results in the city at the end of the first count are: O’Dea, Willie – FF – 8,214 O’Donnell, Kieran – FG – 6,133 Quinlivan, Maurice – SF – 5,936 Ryan, Dee – FF – 2,831 Byrne, Maria – FG – 2,813 O’Donovan, Elisa – SD – 2,808 Sheehan, Conor – Lab – 2,733 Daly, Frankie – Ind – 2,034 Beasley, Sarah – Aon -1,977 Leddin, Brian – GP – 1,782 Gavan, Paul – SF -1,378 Quinn, Dean – IP – 965 Fahy, Ruairí – PBP – 720 Aherne, Esther – II – 688 Cleary, Melanie – IND – 636 Hayes, Michelle – Ind-394 (eliminated) Lillis, Dean – Ind -132 (eliminated)
Share this Story : Spears: Environment Canada dangerously optimistic on climate change action Copy Link Email X Reddit Pinterest LinkedIn Tumblr Breadcrumb Trail Links Opinion Columnists Spears: Environment Canada dangerously optimistic on climate change action Documents finally made public show just how off-base the government has been on climate change. I can’t count the number of targets set up by cities, provinces and the feds. We’ve spectacularly missed each one. Author of the article: Tom Spears Published Nov 27, 2024 • Last updated 6 hours ago • 4 minute read Join the conversation You can save this article by registering for free here . Or sign-in if you have an account. A climate change activist carries a message to Parliament Hill. Photo by Sean Kilpatrick / The Canadian Press Article content Environment Canada recently took five-and-a-half years to answer an Access to Information request from me, and a funny thing happened. The answer became more relevant with time, not less. Here’s why. Article content Article content In April of 2019, the federal government published a study showing that Canada’s climate is warming at about twice the speed of most countries. It wasn’t a big surprise: scientists have said for decades that climate change will be greatest in Earth’s far north and south. The study added fresh details to this. Advertisement 2 Story continues below This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Sign In or Create an Account Email Address Continue or View more offers If you are a Home delivery print subscriber, online access is included in your subscription. Activate your Online Access Now Article content Then my boss asked me: Why are they releasing this study in the same week as the unpopular new carbon tax takes effect? Were they timing their science to justify an unpopular tax? I paid my five bucks back in 2019 and asked for emails inside Environment Canada’s communications office about the study’s release. The answer has finally arrived. It shows no political shenanigans, but something perhaps more disturbing. It shows optimism. Too much blind optimism. And the five-year-old papers take on new relevance when seen through today’s eyes. The 600 pages of emails leading up to the study’s release have all the usual planning: speeches, technical briefings, “infobytes” on Facebook and Twitter. All normal. There are also suggestions on answering media questions. Among them, what if a reporter asks how Canada is doing with our commitment (made in 2015) to cut our greenhouse emissions by 30 per cent by 2030? (Note: That was the target back then. The feds now promise to cut emissions by 40 to 45 per cent.) The suggested response is where things get interesting: “Canada is committed to meeting its Paris Agreement target by 2030. We have a plan to get us there. Advertisement 3 Story continues below This advertisement has not loaded yet, but your article continues below. Article content “Our climate action plan, the Pan-Canadian Framework on Clean Growth and Climate Change, includes over 50 concrete measures to reduce carbon pollution, foster clean technology solutions, and create good jobs that contribute to a stronger economy.” And “Canada’s GHG (greenhouse gas) emissions in 2030 are expected to be 223 million tonnes lower than projected prior to the adoption” of this plan. There’s even better news: “Additional reductions will come from measures that have not yet been modelled ... ” These “will allow Canada to meet its 2030 target and position Canada to set and achieve deeper emission reduction” after 2030. It’s resounding stuff, and important, if accurate. But I don’t think we’re getting anywhere near either the original target for 2030 or the current version. Nine years into the plan, little to show I’ve been covering environment news since 1988, the year when a famous international conference in Toronto, called The Changing Atmosphere , made greenhouse gases big news everywhere. I honestly can’t count the number of targets set up by cities, provinces and the feds since. And we’ve spectacularly missed each one. Not just missed, but flamed out. Remember the Kyoto Protocol, when our emissions went up, not down? Advertisement 4 Story continues below This advertisement has not loaded yet, but your article continues below. Article content And now? Nine years into our 15-year plan (2015 to 2030), we’ve nibbled away at emissions but are nowhere close to the target. By 2022 we cut our emissions by seven per cent, federal figures show . Estimates say we likely reduced another percentage point in 2023. So even the original goal of 30 per cent is a long way off. Yet here are documents talking down to us, not just promising to reach (and surpass) targets but dismissively shrugging off any suggestion that this may be harder than they think. They are selling the bear’s skin before catching the bear. In 2019, I stood at a pre-election news conference where Catherine McKenna, environment minister at the time, explained that our switch from fossil fuels to cleaner electric power would parallel the cellphone revolution, making the Paris climate deal work. New technology would drive this. Details — the hard part — would come later. That’s always the way. A few years back, a group that studies energy policy, led by Monica Gattinger at the University of Ottawa, published a paper on “dangerous optimism” — the tendency of governments to make climate commitments with no idea of how to reach them. I wish Canadian governments would stop this. Advertisement 5 Story continues below This advertisement has not loaded yet, but your article continues below. Article content A parallel thought: Let’s say a government is presented with two options — end all heart disease in two years for $10 billion, or take four years but save some money. What’s the right option? There isn’t one, because no one knows how to end all heart disease, and a cheque and a stupid schedule won’t change that. A plan and a framework didn’t save the world at the Rio Summit (1992) or Kyoto (1997) or Copenhagen, Glasgow, Lima, Sharm El-Sheikh, Dubai and 20-plus other international promise-fests that followed, and they won’t now. Show me you can do the job. Brag later. Journalist Tom Spears is a former Ottawa Citizen environment reporter. Recommended from Editorial Spears: Environment Canada still hasn't answered my carbon-tax query — 5 years later As environment committee approves fee increases, delegates want timely climate change data Article content Share this article in your social network Share this Story : Spears: Environment Canada dangerously optimistic on climate change action Copy Link Email X Reddit Pinterest LinkedIn Tumblr Comments You must be logged in to join the discussion or read more comments. Create an Account Sign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Trending 'Mind boggling' surge in pneumonia cases among children, teens and young adults Local News DND is 'assessing' Ottawa sites for unexploded bombs Defence Watch Government settles Phoenix class-action lawsuit News Public servants could lose big as feds redirect $2B pension surplus, union warns Public Service OCDSB trustees censure colleague, rejecting integrity commissioner's findings News Read Next Latest National Stories Featured Local Savings(All times Eastern) Schedule subject to change and/or blackouts Saturday, Nov. 23 AUSTRALIAN RULES FOOTBALL (WOMEN’S) 3:30 a.m. FS2 — AFL Playoffs: Adelaide at Brisbane, Preliminary Final AUTO RACING 12:55 a.m. (Sunday) ESPN — Formula 1: The Heineken Silver Las Vegas Grand Prix, Las Vegas Strip Circuit, Las Vegas COLLEGE BASKETBALL (MEN’S) Noon FS2 — St. Francis (Pa.) at Georgetown 5 p.m. FS2 — N. Illinois at DePaul COLLEGE BASKETBALL (WOMEN’S) 4 p.m. NBC — Notre Dame at Southern Cal PEACOCK — Notre Dame at Southern Cal COLLEGE CROSS COUNTRY (MEN’S and WOMEN’S) 9:30 a.m. ESPNU — NCAA Championships: From Verona, Wis. COLLEGE FOOTBALL Noon ABC — Mississippi at Florida ACCN — UConn at Syracuse BTN — Iowa at Maryland CBSSN — Sam Houston St. at Jacksonville St. CW — North Carolina at Boston College ESPN — Wake Forest at Miami ESPN2 — SMU at Virginia ESPNU — Yale at Harvard FOX — Indiana at Ohio St. PEACOCK — Illinois at Rutgers 12:45 p.m. SECN — UMass at Georgia 3:30 p.m. ABC — Kentucky at Texas ACCN — Stanford at California BTN — Wisconsin at Nebraska CBS — Penn St. at Minnesota CBSSN — San Diego St. at Utah St. CW — The Citadel at Clemson ESPN — BYU at Arizona St. ESPNU — UCF at West Virginia FOX — Colorado at Kansas FS1 — Northwestern at Michigan 4 p.m. ESPN2 — Pittsburgh at Louisville 4:15 p.m. SECN — Missouri at Mississippi St. 7 p.m. CBSSN — Boise St. at Wyoming CW — Washington St. at Oregon St. FS1 — Baylor at Houston NBC — Army vs. Notre Dame, New York PEACOCK — Army vs. Notre Dame, New York 7:30 p.m. ABC — Alabama at Oklahoma ESPN — Texas A&M at Auburn ESPNU — Marshall at Old Dominion FOX — Iowa St. at Utah 7:45 p.m. SECN — Vanderbilt at LSU 8 p.m. ACCN — Virginia Tech at Duke ESPN2 — Cincinnati at Kansas St. 10:15 p.m. NBC — Southern Cal at UCLA 10:30 p.m. CBSSN — Colorado St. at Fresno St. FS1 — Air Force at Nevada 11 p.m. ESPNU — Florida A&M at Bethune-Cookman (Taped) COLLEGE VOLLEYBALL (WOMEN’S) 8 p.m. BTN — Wisconsin at Nebraska GOLF 1 p.m. GOLF — PGA Tour: The RSM Classic, Third Round, Sea Island Golf Club - Seaside Course, Sea Island, Ga. 4 p.m. GOLF — LPGA Tour: The CME Group Tour Championship, Third Round, Tiburon Golf Club, Naples, Fla. (Taped) 9:30 p.m. GOLF — DP World Tour: The BMW Australian PGA Championship, Final Round, Royal Queensland Golf Club, Brisbane, Australia 1 a.m. (Saturday) GOLF — Asian Tour: The LINK Hong Kong Open, Final Round, Hong Kong Golf Club, Hong Kong HORSE RACING 11:30 a.m. FS1 — NYRA: America’s Day at the Races 3:30 p.m. FS2 — NYRA: America’s Day at the Races 1 a.m. (Sunday) FS2 — The Japan Cup: From Tokyo Racecourse, Tokyo NBA BASKETBALL 5 p.m. NBATV — New York at Utah 8 p.m. NBATV — Memphis at Chicago 10:30 p.m. NBATV — Denver at L.A. Lakers NHL HOCKEY 1 p.m. NHLN — Chicago at Philadelphia 7 p.m. NHLN — Vegas at Montreal SAILING 5 a.m. CBSSN — Sail GP: The Emirates Dubai Sail Grand Prix - Day 1, Dubai, United Arab Emirates 5 a.m. (Sunday) CBSSN — Sail GP: The Emirates Dubai Sail Grand Prix - Day 2, Dubai, United Arab Emirates SOCCER (MEN’S) 7:30 a.m. USA — Premier League: Chelsea at Leicester City 9 a.m. CBSSN — Serie A: Inter Milan at Hellas Verona 10 a.m. USA — Premier League: Brighton & Hove Albion at Bournemouth Noon CBS — USL Championship: Rhode Island at Colorado Springs, Final 12:30 p.m. NBC — Premier League: Tottenham Hotspur at Manchester City 7 p.m. FS2 — Saudi Pro League: Al Hilal at Al Khaleej (Taped) SOCCER (WOMEN’S) 8 p.m. CBS — NWSL Playoffs: Orlando vs. Washington, Final, Kansas City, Mo. TENNIS 7 a.m. TENNIS — Davis Cup Finals Semifinal The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV . (All times Eastern) Schedule subject to change and/or blackouts Sunday, Nov. 24 COLLEGE BASKETBALL (MEN’S) 10:30 a.m. ESPNU — ESPN2 — Myrtle Beach Invitational: TBD, Seventh-Place Game, Conway, S.C. 11 a.m. CBSSN — St. John’s vs. Georgia, Nassau, Bahamas 1 p.m. CBSSN — Rutgers at Kennesaw St. ESPN — Villanova vs. Maryland, Newark, N.J. ESPN2 — Myrtle Beach Invitational: TBD, Third-Place Game, Conway, S.C. 3 p.m. CBSSN — Greenbrier Tip-Off: TBD, Third-Place Game, West White Sulphur Springs, W.V. ESPN — Charleston Classic: TBD, Third-Place Game, Charleston, S.C. 3:30 p.m. ESPN2 — Florida St. vs. UMass, Uncasville, Conn. 5:30 p.m. CBSSN — Greenbrier Tip-Off: TBD, Championship, West White Sulphur Springs, W.V. ESPN — Myrtle Beach Invitational: TBD, Championship, Conway, S.C. 6 p.m. ESPN2 — Charleston Classic: TBD, Fifth-Place Game, Charleston, S.C. ESPNU — Yale vs. Delaware, Uncasville, Conn. 8 p.m. ESPN2 — Myrtle Beach Invitational: TBD, Fifth-Place Game, Conway, S.C. 8:30 p.m. ESPN — Charleston Classic: TBD, Championship, Charleston, S.C. COLLEGE BASKETBALL (WOMEN’S) 1 p.m. PEACOCK — South Florida vs. Louisville, Lake Buena Vista, Fla. 4 p.m. ACCN — Bethune-Cookman at Virginia BTN — Washington St. at Iowa FS1 — South Carolina at UCLA COLLEGE FIELD HOCKEY 1:30 p.m. ESPNU — NCAA Tournament: TBD, Championship, Ann Arbor, Mich. COLLEGE FOOTBALL 12:30 p.m. ESPNU — FCS Football Selection Show COLLEGE VOLLEYBALL (WOMEN’S) Noon ACCN — Stanford at North Carolina 2 p.m. ACCN — California at Duke SECN — South Carolina at Tennessee 3:30 p.m. ESPNU — Southwestern Athletic Tournament: TBD, Championship, Grambling, La. 4 p.m. SECN — Arkansas at Kentucky 6 p.m. SECN — Auburn vs. Oklahoma 7:30 p.m. BTN — Indiana at Ohio St. 8:30 p.m. ESPNU — Mid-Eastern Athletic Tournament: TBD, Championship, Dover, Del. FIGURE SKATING 4 p.m. NBC — ISU: The 2024 Cup of China, Chongqing, China GOLF 1 p.m. GOLF — PGA Tour: The RSM Classic, Final Round, Sea Island Golf Club - Seaside Course, Sea Island, Ga. NBC — LPGA Tour: The CME Group Tour Championship, Final Round, Tiburon Golf Club, Naples, Fla. HORSE RACING Noon FS1 — NYRA: America’s Day at the Races 4 p.m. FS2 — NYRA: America’s Day at the Races NBA G-LEAGUE BASKETBALL 1 p.m. NBATV — Capital City at Maine NFL FOOTBALL 1 p.m. CBS — Regional Coverage: New England at Miami, Tampa Bay at N.Y. Giants, Kansas City at Carolina, Tennessee at Houston FOX — Regional Coverage: Minnesota at Chicago, Detroit at Indianapolis, Dallas at Washington 4:05 p.m. CBS — Denver at Las Vegas 4:25 p.m. FOX — Regional Coverage: San Francisco at Green Bay, Arizona at Seattle 8:20 p.m. NBC — Philadelphia at L.A. Rams PEACOCK — Philadelphia at L.A. Rams NHL HOCKEY 7 p.m. NHLN — Utah at Toronto SAILING 5 a.m. CBSSN — Sail GP: The Emirates Dubai Sail Grand Prix - Day 2, Dubai, United Arab Emirates SOCCER (MEN’S) 9 a.m. USA — Premier League: Liverpool at Southampton 11:30 a.m. USA — Premier League: Manchester United at Ipswich Town 11:45 a.m. FS2 — Saudi Pro League: Al Fateh at Al Ittihad Noon ABC — Spanish Primera Division: Real Madrid at CD Leganés 6 p.m. FS1 — MLS Cup Western Conference Semifinal: Minnesota at L.A. Galaxy TENNIS 10 a.m. TENNIS — Davis Cup Finals Championship The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.comSouth Florida sees dozens of luxury high-rise buildings start to sinkThe New York Knicks have become one of the best offenses in the NBA with the addition of Karl-Anthony Towns. It's why the team was able to win their last four contests including Wednesday night in a blowout win. There has been a clear issue with the team to start the season, though. Towns was never a top defender at the center position. It's a big reason why New York's defense is ranked 13th in the league in points per game. Luckily for New York, there is help on the way. Brad Penner-Imagn Images New York hasn't had defensive star Mitchell Robinson on the court over the last few months due to an ankle injury. For the first time this season, the top defender joined the team on the road trip to Phoenix and has started shooting on the side. It's something that head coach Tom Thibodeau has been pleased to update. “It’s going to be a long progression. So obviously he started but be patient, go step by step," Thibodeau explained. “He hasn’t been cleared for practice but he’s done some shooting and that sort of thing. Can do conditioning in the weight room. “He’s making good progress. Just have to be patient.” Related: Knicks Roll Past Banged-Up Suns, 138-122 Most analysts have expected Robinson to return somewhere after the new year, and it should allow New York to fix their defensive woes. When healthy, Robinson is one of the better defenders in his position. He's been a defensive stalwart against top matchups like Joel Embiid in previous playoff series, and someone New York desperately needs to complete their roster. And his return is coming sooner than later. Related: How Does Mickey Mouse Connect with Knicks?
Coherent Holds An Nvidia-Like Gain. AI Is Just One Reason Why.
Some elite US universities favor wealthy students in admissions decisions, lawsuit allegesCOLUMBIA, Mo. (AP) — Arkansas defensive end Landon Jackson was carted off the field and taken to a hospital with a neck injury late in the first half of Saturday's game at No. 24 Missouri. Jackson appeared to injure his neck while trying to tackle Missouri running back Jamal Roberts. Medical personnel tended to Jackson for approximately 10 minutes before he was placed on a backboard and driven to a waiting ambulance. Jackson gave a thumbs-up sign as he was carted off the snow-covered field. Arkansas athletic director Hunter Yurachek said Jackson had movement in his arms and legs but was experiencing pain in his neck. He said Jackson was taken to the hospital as a precaution. Jackson leads the Razorbacks with 9 1/2 tackles for loss and 6 1/2 sacks, and is considered a potential first-round pick in next year's NFL draft. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up . AP college football: and David Solomon, The Associated Press
Amwell CFO Mark Hirschhorn Expands Leadership Role
AI-generated deepfake videos are a rapidly growing security concern, with recent reports showing 75 percent of organisations have experienced at least one deepfake-related incident within the last 12 months. Digital PR Agency , which represents the types of sectors that might be affected, has provided some advice to Digital Journal on how to spot deepfake videos. Verify the source and context Fake news spread more rapidly than true news on X (previously Twitter), a concerning trend given that nearly 30 percent of Americans rely on social media as a regular news source. Always examine the credibility of the sources behind the content you consume. Is this information coming from a reputable news outlet or a verified official account? If the source is unfamiliar or looks dubious, cross-check the content’s authenticity using reliable news organisations or fact-checking platforms like Google Fact Check Tools. Misinformation often plays on emotional triggers like fear, anger, or outrage to cloud your judgement. When you encounter content that provokes strong emotions, pause and re-assess to ensure you are not being used as a pawn in someone’s game. Observe facial expressions and movements Deepfakes often falter when trying to replicate the intricate details of facial expressions and natural movements. Key areas to scrutinise include microexpressions around the eyes and mouth. Look out for unnatural blinking patterns, disjointed eye movements, or jerky head motions, and check whether the facial expressions align with the conveyed emotions. Details like the uniformity of teeth, hair texture, and facial structure can also reveal deepfakes. A key giveaway is the shape of the face and ears – deepfakes often have slightly off measurements in these areas, with ears being particularly difficult to replicate. Pausing the video and examining the facial features can help you spot these irregularities. Use reverse image and video search tools Leverage reverse image and video search tools to trace the origins of visual content. Uploading an image to Google Reverse Image Search can help identify if it’s AI-generated, manipulated, or being used out of context. For videos, tools like InVID can dissect footage and check for any modifications or previous appearances. These searches allow you to find other copies of the image online, helping you verify its authenticity and uncover potential misuses. Look for digital artefacts and inconsistencies Deepfakes often reveal themselves through subtle digital flaws like blurriness or unnatural pixelation, especially around the edges of faces or objects. Pay attention to inconsistencies in lighting, shadows, reflections, or even an extra finger, that might indicate manipulation. Check for audio-visual synchronisation Spotting a deepfake often comes down to watching the lips closely. Our mouths form specific shapes when pronouncing certain letters, and these movements are tricky for AI to replicate accurately – nearly a third of deepfake videos struggle to match sounds like M, B and P. Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news.Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.Trump’s promises to conservatives raise fears of more book bans in US
Arkansas DE Landon Jackson carted off field and taken to hospital with neck injury
NEW YORK (AP) — U.S. stock indexes rose to more records Wednesday after tech companies talked up how much of a boost they’re getting from the artificial-intelligence boom. The S&P 500 climbed 0.6% to add to what’s set to be one of its best years of the millennium. It’s the 56th time the index has hit an all-time high this year after climbing in 11 of the last 12 days . The Dow Jones Industrial Average rose 308 points, or 0.7%, while the Nasdaq composite added 1.3% to its own record. Salesforce helped pull the market higher after delivering stronger revenue for the latest quarter than analysts expected, though its profit fell just short. CEO Mark Benioff highlighted the company’s artificial-intelligence offering for customers, saying “the rise of autonomous AI agents is revolutionizing global labor, reshaping how industries operate and scale.” The stock price of the company, which helps businesses manage their customers, jumped 11%. Marvell Technology leaped even more after delivering better results than expected, up 23.2%. CEO Matt Murphy said the semiconductor supplier is seeing strong demand from AI and gave a forecast for profit in the upcoming quarter that topped analysts’ expectations. All the optimistic talk helped Nvidia , the company whose chips are powering much of the move into AI, rally 3.5%. It was the strongest force pushing upward on the S&P 500 by far. They helped offset an 8.9% drop for Foot Locker, which reported profit and revenue that fell short of analysts’ expectations. CEO Mary Dillon said the company is taking a more cautious view, and it cut its forecasts for sales and profit this year. Dillon pointed to how keen customers are for discounts and how soft demand has been outside of Thanksgiving week and other key selling periods. Retailers overall have offered mixed signals about how resilient U.S. shoppers can remain. Their spending has been one of the main reasons the U.S. economy has avoided a recession that earlier seemed inevitable after the Federal Reserve hiked interest rates to crush inflation. But shoppers are now contending with still-high prices and a slowing job market . This week’s highlight for Wall Street will be Friday’s jobs report from the U.S. government, which will show how many people employers hired and fired last month. A narrower report released Wednesday morning suggested employers in the private sector increased their payrolls by less last month than economists expected. Hiring in manufacturing was the weakest since the spring, according to Nela Richardson, chief economist at ADP. The report strengthened traders’ expectations that the Fed will cut its main interest rate again when it meets in two weeks. The Fed began easing its main interest rate from a two-decade high in September, hoping to offer more support for the job market. The central bank had appeared set to continue cutting rates into next year, but the election of Donald Trump has scrambled Wall Street’s expectations somewhat. Trump’s preference for higher tariffs and other policies could lead to higher inflation , which could alter the Fed’s plans . Story continues below video Fed Chair Jerome Powell said Wednesday that the central bank can afford to cut rates cautiously because inflation has slowed from its peak two years ago and the economy remains sturdy. A separate report on Wednesday said health care, finance and other businesses in the U.S. services sector are continuing to grow, but not by as much as before and not by as much as economists expected. One respondent from the construction industry told the survey from the Institute for Supply Management that the Fed’s rate cuts haven't pulled down mortgage rates as much as hoped. Plus, “the unknown effect of tariffs clouds the future.” In the bond market, the yield on the 10-year Treasury fell to 4.18% from 4.23% late Tuesday. On Wall Street, Campbell’s sank 6.2% for one of the S&P 500’s sharper losses despite increasing its dividend and reporting a stronger profit than analysts expected. Its revenue fell short of Wall Street’s expectations, and the National Football League’s Washington Commanders hired Campbell’s CEO Mark Clouse as its team president. Gains for airline stocks helped offset that drop after JetBlue Airways said it saw stronger bookings for travel in November and December following the presidential election. It also said it’s benefiting from lower fuel prices, as well as lower costs due to improved on-time performance. JetBlue jumped 8.3%, while Southwest Airlines climbed 3.5%. All told, the S&P 500 rose 36.61 points to 6,086.49. The Dow climbed 308.51 to 45,014.04, and the Nasdaq composite rallied 254.21 to 19,735.12. In stock markets abroad, South Korea’s Kospi sank 1.4% following a night full of drama in Seoul. President Yoon Suk Yeol was facing possible impeachment after he suddenly declared martial law on Tuesday night, prompting troops to surround the parliament. He revoked the martial law declaration six hours later. In the crypto market , bitcoin climbed near $99,000 after Trump said he would nominate Paul Atkins , a cryptocurrency advocate, to chair the Securities and Exchange Commission. AP Writers Matt Ott and Zimo Zhong contributed.House rejects Democratic efforts to force release of Matt Gaetz ethics reportSome elite US universities favor wealthy students in admissions decisions, lawsuit alleges